HOLON, Israel, May 10, 2022
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage
cancer immunotherapy company and a pioneer in computational target
discovery, announced today that Mr. Ari
Krashin, Chief Financial Officer and Chief Operating Officer
of Compugen Ltd. (the "Company"), notified the Company of his wish
to depart from his position at the Company to pursue other
interests. Mr. Krashin will leave in August
2022 and, until his departure, he will continue to support
the Company in his current roles. The departure is not related to
any matter connected with the Company's operations, policies or
practices.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody, for the treatment of solid tumors, in Phase 1 as a
single agent and in dual, and triple combinations;
COM902, a potential best-in-class monoclonal antibody
targeting TIGIT for the treatment of solid and hematological
tumors, undergoing Phase 1 studies as a single agent and in dual
combination with COM701. Partnered programs include bapotulimab an
antibody targeting ILDR2 in Phase 1 development, licensed to Bayer
under a research and discovery collaboration and license agreement,
and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase
1/2 development by AstraZeneca through a license agreement for the
development of bispecific and multi-specific antibodies. In
addition, the Company's therapeutic pipeline of early-stage
immuno-oncology programs consists of programs aiming to address
various mechanisms of immune resistance, including myeloid targets.
Compugen is headquartered in Israel, with offices in South San Francisco,
CA. Compugen's shares are listed on Nasdaq and the Tel
Aviv Stock Exchange under the ticker symbol CGEN.
Investor Relations contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications Compugen
Ltd.
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-announces-cfo-departure-301543524.html
SOURCE Compugen Ltd.